The kinetics of specific immune responses in rhesus monkeys inoculated with live recombinant BCG expressing SIV Gag, Pol, Env, and Nef proteins

Nancy J. Leung, Anna Aldovini, Richard Young, Michael A. Jarvis, James M. Smith, Debra Meyer, David E. Anderson, Maria P. Carlos, Murray B. Gardner, Jose V Torres

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Development of an effective preventive or therapeutic vaccine against HIV-1 is an important goal in the fight against AIDS. Effective virus clearance and inhibition of spread to target organs depends principally on the cellular immune response. Therefore, a vaccine against HIV-1 should elicit virus-specific cytotoxic lymphocyte (CTL) responses to eliminate the virus during the cell-associated stages of its life cycle. The vaccine should also be capable of inducing immunity at the mucosal surfaces, the primary route of transmission. Recombinant Bacille Calmette-Guerin (BCG) expressing viral proteins offers an excellent candidate vaccine in view of its safety and ability to persist intracellularly, resulting in the induction of long-lasting immunity and stimulation of the cellular immune response. BCG can be administered orally to induce HIV-specific immunity at the mucosal surfaces. The immunogenicity of four recombinant BCG constructs expressing simian immunodeficiency virus (SIV) Gag, Pol, Env, and Nef proteins was tested in rhesus macaques. A single simultaneous inoculation of all four recombinants elicited SIV-specific IgA and IgG antibody, and cellular immune responses, including CTL and helper T cell proliferation. Our results demonstrate that BCG recombinant vectors can induce concomitant humoral and cellular immune responses to the major proteins of SIV. (C) 2000 Academic Press.

Original languageEnglish (US)
Pages (from-to)94-103
Number of pages10
JournalVirology
Volume268
Issue number1
DOIs
StatePublished - Mar 1 2000

Fingerprint

gag-pol Fusion Proteins
nef Gene Products
env Gene Products
Simian Immunodeficiency Virus
Macaca mulatta
Cellular Immunity
Vaccines
Mucosal Immunity
Viruses
HIV-1
Lymphocytes
Viral Proteins
Humoral Immunity
Helper-Inducer T-Lymphocytes
Life Cycle Stages
Immunoglobulin A
Immunity
Acquired Immunodeficiency Syndrome
Immunoglobulin G
Cell Proliferation

ASJC Scopus subject areas

  • Virology
  • Infectious Diseases

Cite this

The kinetics of specific immune responses in rhesus monkeys inoculated with live recombinant BCG expressing SIV Gag, Pol, Env, and Nef proteins. / Leung, Nancy J.; Aldovini, Anna; Young, Richard; Jarvis, Michael A.; Smith, James M.; Meyer, Debra; Anderson, David E.; Carlos, Maria P.; Gardner, Murray B.; Torres, Jose V.

In: Virology, Vol. 268, No. 1, 01.03.2000, p. 94-103.

Research output: Contribution to journalArticle

Leung, NJ, Aldovini, A, Young, R, Jarvis, MA, Smith, JM, Meyer, D, Anderson, DE, Carlos, MP, Gardner, MB & Torres, JV 2000, 'The kinetics of specific immune responses in rhesus monkeys inoculated with live recombinant BCG expressing SIV Gag, Pol, Env, and Nef proteins', Virology, vol. 268, no. 1, pp. 94-103. https://doi.org/10.1006/viro.1999.0131
Leung, Nancy J. ; Aldovini, Anna ; Young, Richard ; Jarvis, Michael A. ; Smith, James M. ; Meyer, Debra ; Anderson, David E. ; Carlos, Maria P. ; Gardner, Murray B. ; Torres, Jose V. / The kinetics of specific immune responses in rhesus monkeys inoculated with live recombinant BCG expressing SIV Gag, Pol, Env, and Nef proteins. In: Virology. 2000 ; Vol. 268, No. 1. pp. 94-103.
@article{3c804c231b614094ae39d10fb35710d1,
title = "The kinetics of specific immune responses in rhesus monkeys inoculated with live recombinant BCG expressing SIV Gag, Pol, Env, and Nef proteins",
abstract = "Development of an effective preventive or therapeutic vaccine against HIV-1 is an important goal in the fight against AIDS. Effective virus clearance and inhibition of spread to target organs depends principally on the cellular immune response. Therefore, a vaccine against HIV-1 should elicit virus-specific cytotoxic lymphocyte (CTL) responses to eliminate the virus during the cell-associated stages of its life cycle. The vaccine should also be capable of inducing immunity at the mucosal surfaces, the primary route of transmission. Recombinant Bacille Calmette-Guerin (BCG) expressing viral proteins offers an excellent candidate vaccine in view of its safety and ability to persist intracellularly, resulting in the induction of long-lasting immunity and stimulation of the cellular immune response. BCG can be administered orally to induce HIV-specific immunity at the mucosal surfaces. The immunogenicity of four recombinant BCG constructs expressing simian immunodeficiency virus (SIV) Gag, Pol, Env, and Nef proteins was tested in rhesus macaques. A single simultaneous inoculation of all four recombinants elicited SIV-specific IgA and IgG antibody, and cellular immune responses, including CTL and helper T cell proliferation. Our results demonstrate that BCG recombinant vectors can induce concomitant humoral and cellular immune responses to the major proteins of SIV. (C) 2000 Academic Press.",
author = "Leung, {Nancy J.} and Anna Aldovini and Richard Young and Jarvis, {Michael A.} and Smith, {James M.} and Debra Meyer and Anderson, {David E.} and Carlos, {Maria P.} and Gardner, {Murray B.} and Torres, {Jose V}",
year = "2000",
month = "3",
day = "1",
doi = "10.1006/viro.1999.0131",
language = "English (US)",
volume = "268",
pages = "94--103",
journal = "Virology",
issn = "0042-6822",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - The kinetics of specific immune responses in rhesus monkeys inoculated with live recombinant BCG expressing SIV Gag, Pol, Env, and Nef proteins

AU - Leung, Nancy J.

AU - Aldovini, Anna

AU - Young, Richard

AU - Jarvis, Michael A.

AU - Smith, James M.

AU - Meyer, Debra

AU - Anderson, David E.

AU - Carlos, Maria P.

AU - Gardner, Murray B.

AU - Torres, Jose V

PY - 2000/3/1

Y1 - 2000/3/1

N2 - Development of an effective preventive or therapeutic vaccine against HIV-1 is an important goal in the fight against AIDS. Effective virus clearance and inhibition of spread to target organs depends principally on the cellular immune response. Therefore, a vaccine against HIV-1 should elicit virus-specific cytotoxic lymphocyte (CTL) responses to eliminate the virus during the cell-associated stages of its life cycle. The vaccine should also be capable of inducing immunity at the mucosal surfaces, the primary route of transmission. Recombinant Bacille Calmette-Guerin (BCG) expressing viral proteins offers an excellent candidate vaccine in view of its safety and ability to persist intracellularly, resulting in the induction of long-lasting immunity and stimulation of the cellular immune response. BCG can be administered orally to induce HIV-specific immunity at the mucosal surfaces. The immunogenicity of four recombinant BCG constructs expressing simian immunodeficiency virus (SIV) Gag, Pol, Env, and Nef proteins was tested in rhesus macaques. A single simultaneous inoculation of all four recombinants elicited SIV-specific IgA and IgG antibody, and cellular immune responses, including CTL and helper T cell proliferation. Our results demonstrate that BCG recombinant vectors can induce concomitant humoral and cellular immune responses to the major proteins of SIV. (C) 2000 Academic Press.

AB - Development of an effective preventive or therapeutic vaccine against HIV-1 is an important goal in the fight against AIDS. Effective virus clearance and inhibition of spread to target organs depends principally on the cellular immune response. Therefore, a vaccine against HIV-1 should elicit virus-specific cytotoxic lymphocyte (CTL) responses to eliminate the virus during the cell-associated stages of its life cycle. The vaccine should also be capable of inducing immunity at the mucosal surfaces, the primary route of transmission. Recombinant Bacille Calmette-Guerin (BCG) expressing viral proteins offers an excellent candidate vaccine in view of its safety and ability to persist intracellularly, resulting in the induction of long-lasting immunity and stimulation of the cellular immune response. BCG can be administered orally to induce HIV-specific immunity at the mucosal surfaces. The immunogenicity of four recombinant BCG constructs expressing simian immunodeficiency virus (SIV) Gag, Pol, Env, and Nef proteins was tested in rhesus macaques. A single simultaneous inoculation of all four recombinants elicited SIV-specific IgA and IgG antibody, and cellular immune responses, including CTL and helper T cell proliferation. Our results demonstrate that BCG recombinant vectors can induce concomitant humoral and cellular immune responses to the major proteins of SIV. (C) 2000 Academic Press.

UR - http://www.scopus.com/inward/record.url?scp=18244423060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18244423060&partnerID=8YFLogxK

U2 - 10.1006/viro.1999.0131

DO - 10.1006/viro.1999.0131

M3 - Article

C2 - 10683331

AN - SCOPUS:18244423060

VL - 268

SP - 94

EP - 103

JO - Virology

JF - Virology

SN - 0042-6822

IS - 1

ER -